Search results
Feb 27, 2023 · PETALING JAYA: Pharmaniaga Bhd has been classified as an affected listed issuer under Practice Note 17 (PN17) of the Main Market Listing Requirements of Bursa Malaysia.
- PHARMA (7081), PHARMANIAGA BHD - Market Watch | The Star
Stock overview for PHARMANIAGA BHD (PHARMA, 7081) on Bursa...
- Pharmaniaga says 'stands firm' on financial recovery to exit PN17
The group assured shareholders of its strong and steady...
- Pharmaniaga to focus on exiting PN17 status | The Star
PETALING JAYA: Pharmaniaga Bhd will focus on targeted...
- PHARMA (7081), PHARMANIAGA BHD - Market Watch | The Star
Jun 12, 2023 · PETALING JAYA, 12 June 2023 – Pharmaniaga Berhad (Pharmaniaga) outlines a strategic plan to address the challenges presented by its Practice Note 17 (PN17) status, with a strong focus on financial recalibration and a resolute commitment to overcome obstacles.
May 10, 2024 · The group assured shareholders of its strong and steady progress, "backed by resilient business fundamentals and well-defined strategies to exit its Practice Note 17 status (PN17).”
Jun 13, 2023 · PETALING JAYA: Pharmaniaga Bhd will focus on targeted initiatives aimed at streamlining business activities to exit its Practice Note 17 (PN17) status. In a statement, executive committee chairman ...
Feb 23, 2024 · KUALA LUMPUR: Pharmaniaga Bhd has submitted its regularisation plan to Bursa Malaysia Securities Bhd (Bursa Securities) as the company bids to exit its Practice Note 17 (PN17) status.
Jun 13, 2023 · Pharmaniaga Bhd (Pharmaniaga) outlines a strategic plan to address the challenges presented by its Practice Note 17 (PN17) status, with a strong focus on financial recalibration and a resolute commitment to overcome obstacles.
Feb 28, 2023 · Bursa Malaysia Securities Berhad has announced the inclusion of Pharmaniaga Berhad in the PN17 list after the company triggered the criteria of the Main Market Listing Requirements of Bursa Securities.